EPITAN - Clinuvel Pharmaceuticals

EPITANAppendicesThe board and senior management of EpiTan comprise individuals from severaldifferent geographic regions, which we believe will benefit the company in theprogression of global late stage clinical trials and partnering of MELANOTAN. Theboard has also been involved in a wide range of aspects of pharmaceuticaldevelopment and commercialisation.In addition, the company has engaged a number of consultants and has collaborativeresearch relationships with leading research institutions to provide specialistknowledge where required.Senior managementIain KirkwoodChief ExecutiveMr Kirkwood has, over the last 25 years, held a range of senior financial positions withmajor public companies in Australia, Britain and the US, including F.H. Faulding & Co.Limited, Santos Limited and Pilkington plc. Mr Kirkwood is currently also a NonExecutive Director of Medical Developments International Limited (ASX: MVP) andVision Group Holdings Limited (ASX: VGH).He is a Chartered Accountant, CPA, former President of the Finance and TreasuryAssociation of Australia and a member of the Institute of Company Directors.Dr Stuart HumphreyManager Clinical DevelopmentDr Humphrey joined EpiTan in 2001. He has an Honours degree in Biochemistry fromthe University of Liverpool and a Doctorate of Philosophy from the University ofAuckland with over 35 years experience in research and pharmaceutical projectmanagement.He has held the positions of Regional Operations Manager at Omnicare ClinicalResearch, a large international clinical research organization, and Regulatory AffairsManager and Manager Scientific Clinical Development with Bristol-Myers Squibb inAustralia and New Zealand.Michael KleinigManager Pharmaceutical & New Business DevelopmentMr Kleinig joined EpiTan in 2001. He was formerly a Senior Research Scientist at CSLLimited where he was employed for 15 years, working in research and development inboth the Pharmaceutical and Bioplasma divisions. He graduated from SwinburneInstitute of Technology with a double major in Applied Chemistry and Biochemistry.Chris RossidisManager Pharmaceutical ProductsMr Rossidis has broad experience of the pharmaceutical industry after spending 15years in sales and marketing roles at Eli Lilly, Glaxo Welcome and latterly CSL. AsCSL's Business Development Manager, he was responsible for supporting CSL'sgrowth through identifying and evaluating new prescription medicine business.Dr Dennis WrightManager Regulatory AffairsDr Wright has a broad range of experience in the pharmaceutical industry spanningnearly 25 years. He spent over 17 years at CSL Limited (ASX: CSL) workingpredominantly in regulatory affairs with nearly a decade as Regulatory AffairsManager. During this time Dr Wright was responsible for the registration of a number akey products in Australia and the management of regulatory strategy for developmentprojects. Most recently he was Pharmacovigilance and Regulatory Affairs Manager forthe Australian and New Zealand operations of Mayne Pharma (ASX: MAY). Dr Wright22